ApoptiCIDe-RGT-MitoX-002

ApoptiCIDe-RGT-MitoX-002 is a regulated gene therapy candidate being developed by Phoenix SENOLYTIX for the treatment of age-related disorders. It is part of the company's ApoptiCIDe-RGT™ platform, which utilizes proprietary MitoXcel technology to target mitochondrial function. The therapy is designed to address mitochondrial dysfunction, a key driver of aging and age-related pathologies. The ApoptiCIDe platform incorporates an enhanced cell elimination switch technology, originally developed as CaspaCIDe, which has been reimagined for in vivo regulated gene therapy applications. This allows for controlled gene expression or cell elimination to ensure safety and efficacy in treating chronic age-related conditions.